MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
13.67
+0.59
+4.51%
After Hours: 13.58 -0.09 -0.66% 19:32 01/21 EST
OPEN
13.21
PREV CLOSE
13.08
HIGH
13.74
LOW
13.15
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
25.34
52 WEEK LOW
12.06
MARKET CAP
1.17B
P/E (TTM)
-3.7643
1D
5D
1M
3M
1Y
5Y
1D
Syndax Looks Tantalizing, But Looks Can Be Deceptive
Seeking Alpha · 5h ago
Weekly Report: what happened at SNDX last week (0113-0117)?
Weekly Report · 1d ago
Incyte And Syndax : FDA Approves Niktimvo 9 Mg And 22 Mg Vial Sizes
NASDAQ · 6d ago
Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes
Dow Jones · 6d ago
Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials
Seeking Alpha · 6d ago
Incyte, Syndax announce FDA approval for Niktimvo vial sizes
TipRanks · 6d ago
Incyte, Syndax Announce FDA Approval Of Niktimvo 9 mg And 22 mg Vial Sizes; US Launch Expected In Early February
Benzinga · 6d ago
INCYTE CORP - NIKTIMVO EXPECTED TO BE AVAILABLE IN U.S. IN EARLY FEBRUARY
Reuters · 6d ago
More
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.